NCT03736850View on ClinicalTrials.gov

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 19, 2018

Primary Completion Date

May 15, 2020

Study Completion Date

May 15, 2020

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

CS3006

"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."

Trial Locations (1)

Unknown

People's Liberation Army 307 Hospital, Beijing

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY

NCT03736850 - Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter